Reactome | Autophosphorylation of PDGF alpha receptors

Autophosphorylation of PDGF alpha receptors

Stable Identifier

R-HSA-389083

Type

Reaction [transition]

Species

Homo sapiens

Compartment

cytosol, plasma membrane

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Autophosphorylation of PDGF alpha receptors

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Receptor dimerisation is key event in PDGF receptor activation. The intracellular regions of the receptors are juxtaposed which allows trans-phosphorylation between the two receptors in the complex.
The autophosphorylation site Y857 located inside the kinase domain of beta-receptor (PDGFRB) is important for activation of the kinase. This tyrosine is conserved in the alpha-receptor (PDGFRA), where it corresponsds to Y849, and in almost all other tyrosine kinase receptors. The other known autophosphorylation sites are localized outside the kinase domains of the alpha- and beta- receptors; of the 15( beta) or 16 (alpha) tyrosine residues in the intracellular, non-catalytic part of the beta- or alpha receptor, 11 and 10, respectively, are autophosphorylation sites (reviewed in Heldin et al, 1998).
PDGFRA and PDGFRB activity can be inhibited by binding to type I and type II tyrosine kinase inhibitors (reviewed in Roskoski, 2018). Type I inhibitors such as crenolanib, avripatinib and pazopanib, bind to the active conformation of the receptor and inhibit trans-autophosphorylation (Ip et al, 2018; Evans et al, 2017; Davids et al, 2009; reviewed in Roskoski, 2018; Klug et al, 2018; Papadopoulos and Lennartsson, 2016).

Literature References

PubMed ID	Title	Journal	Year
29408302	The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders Roskoski, R	Pharmacol. Res.	2018
30389923	Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies Ip, CKM, Ng, PKS, Jeong, KJ, Shao, SH, Ju, Z, Leonard, PG, Hua, X, Vellano, CP, Woessner, R, Sahni, N, Scott, KL, Mills, GB	Nat Commun	2018
9739761	Signal transduction via platelet-derived growth factor receptors Heldin, CH, Ostman, A, Rönnstrand, L	Biochim Biophys Acta	1998
29964125	Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases Klug, LR, Kent, JD, Heinrich, MC	Pharmacol. Ther.	2018
29093181	A precision therapy against cancers driven by KIT/PDGFRA mutations Evans, EK, Gardino, AK, Kim, JL, Hodous, BL, Shutes, A, Davis, A, Zhu, XJ, Schmidt-Kittler, O, Wilson, D, Wilson, K, DiPietro, L, Zhang, Y, Brooijmans, N, LaBranche, TP, Wozniak, A, Gebreyohannes, YK, Schöffski, P, Heinrich, MC, Deangelo, DJ, Miller, S, Wolf, B, Kohl, N, Guzi, T, Lydon, N, Boral, A, Lengauer, C	Sci Transl Med	2017
29137923	The PDGF/PDGFR pathway as a drug target Papadopoulos, N, Lennartsson, J	Mol. Aspects Med.	2018
19564526	Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma Davids, MS, Davids, M, Charlton, A, Ng, SS, Chong, ML, Laubscher, K, Dar, M, Hodge, J, Soong, R, Goh, BC	J. Clin. Oncol.	2009